ulmonary Arterial Hypertension (PAH) is a severe pulmonary vascular disease and often progresses rapidly toward right ventricular (RV) failure and death if left untreated.
RV myocardial performance (Tei) index, RV-free wall systolic strain, RV dyssynchrony, and tricuspid annular plane systolic excursion (TAPSE) are all suggested to be associated with outcome in adults with PAH and such predictors now gain an increasing role in therapeutic decision-making. 18, 19, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] In pediatric PAH, however, the value of echocardiography in assessing prognosis and therapeutic decision-making has been studied only anecdotally and incompletely. [34] [35] [36] [37] [38] [39] Isolated echocardiographic measurements in children with PAH, such as RV systolic to diastolic duration ratio or tissue Doppler measurement of early diastolic myocardial relaxation velocity or tricuspid annular peak systolic velocity (S′), have been reported to be associated with clinical outcome. [34] [35] [36] Because many diagnostic tools used to guide management in adult PAH may be not or less feasible in children (ie, 6MWD, right heart catheterization [RHC] requiring sedation or anesthesia), the need for noninvasive tools that are feasible also in young children is urgent. Recently, cMRI has been suggested as a promising tool for guiding management in pediatric PAH, but accessibility to required infrastructure and expertise is not (yet) widely available to physicians treating children with PAH. [11] [12] [13] In contrast, echocardiography is noninvasive and easily obtainable also in small children, allowing for repetitive measurements and thus longitudinal follow-up. Quality of echocardiographic windows is known to be superior in children compared with adults. In this early study, we evaluate the value of conventional transthoracic echocardiography in children with PAH, by describing correlations between multiple echo variables and disease severity and outcome.
Methods

Study Design and Population
Between 2004 and 2010, 43 consecutive children with idiopathic PAH and PAH associated with congenital heart disease (PAH-CHD), confirmed by RHC, were enrolled in a registry-based prospective observational study. In the Netherlands, all children with PAH are referred to the University Medical Center Groningen, the national referral center of the Dutch National Network for Pediatric Pulmonary Hypertension. 6 In this ongoing registry, all patients have standardized follow-up visits at least twice a year. Data on RHC, 6MWD, echocardiography, and serum markers are prospectively collected with written informed consent from the parents or caregivers and institutional review board approval.
Echocardiographic Measurements
In 2004, a study protocol for transthoracic echocardiography, including predefined two-dimensional (2D)-anatomic variables, color Doppler flow variables, and tissue Doppler imaging variables, was designed and since then performed in all children with PAH who visited the referral center. The echo-study was performed by 2 specifically trained echocardiographers, using a Vivid 7 ultrasound scanner (GE-Vingmed Ultrasound AS, Benelux, Brussels, Belgium). In each patient, the first echo-study according to this protocol was used for the baseline analysis. The second echo-study, obtained during follow-up, was used for follow-up analysis. The echo-protocol included 41 echo variables (Table I in the Data Supplement). 2D-anatomic measurements and (tissue-) Doppler measurements were performed according to the pediatric guidelines of the American Society of Echocardiography. 40 Three consecutive cardiac cycles were recorded during expiration and were analyzed using offline quantification software (General Electric, Echopac, Benelux, Brussels, Belgium). The off-line measurements were performed by a trained echocardiographer (D.v.d.W.) blinded for clinical data.
Disease Severity and Outcome
Echo variables at baseline were correlated with disease severity and outcome. Disease severity correlates were performed using WHO-FC and NT-pro-BNP, which were assessed within a period of 2 weeks from the echo-study. WHO-FC was determined by 2 pediatric cardiologists, who were responsible for the daily medical care of the patients. NT-pro-BNP was measured by electrochemiluminescence (Elecsys, Roche Diagnostics, Basel, Switzerland). Outcome was defined as death or lung-transplantation (transplant-free survival). The follow-up time was calculated from the echo-study until death, lungtransplantation, or the last follow-up visit before October 2013.
Hemodynamics: A Subgroup Analysis
Patients in whom RHC was performed within 2 months from the baseline echo-study were included in a subgroup analysis to evaluate the correlation between echocardiography and invasively obtained hemodynamic measures, previously reported to predict prognosis in pediatric PAH: mean right atrial pressure, indexed pulmonary vascular resistance, cardiac index, and mean pulmonary-to-systemic arterial pressure ratio.
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Statistical Analysis
Data analysis was performed using IBM SPSS 22.0 (Armonk, NY). Data were presented as number (percentage) for dichotomous or categorical data, mean±SD for normally distributed continuous data or median (interquartile range [IQR]) for not-normally distributed continuous data. The distribution of the data was visually inspected using quantile-quantile plots in which quantiles from the data were plotted against expected quantiles from the standard normal distribution. 42, 43 Sample skewness and kurtosis statistics were assessed for every studied variable. These were generated in IBM SPSS by calculating adjusted Fisher-Pearson standardized moment coefficients, which is the standard skewness/kurtosis calculating method in most statistical software packages. 43 Only variables with both skewness and kurtosis coefficient values between −2 and 2 were considered acceptably normally distributed. Log-transformation was used to normalize the distribution of NT-pro-BNP. The multiple imputation functionality in IBM SPSS with fully conditional specification was used to impute missing values for variables with <50% missing data, which met the missing at random assumption. Pooled analyses were performed on 15 imputed data sets, generated using multiple imputation with 20 iterations. 44 Categorical variables were compared using χ 2 test or Fisher exact test in case of expected cell frequencies <5. Continuous variables were compared using t test or ANOVA (normally distributed variables) and Mann-Whitney U test or Kruskal-Wallis (not-normally distributed variables). Correlations involving not-normally distributed or ordinal variables were assessed using Spearman correlation analysis. Pearsons correlation analysis was used to assess correlations between normally distributed continuous variables.
Survival of the full cohort was depicted with Kaplan-Meier curves stratified by WHO-FC and survival differences were compared by means of a log-rank test. Cox proportional hazard analysis was used in the assessment of the correlation of echo variables with transplantfree survival. A separate Cox regression analysis was performed to assess the correlation of the first follow-up echo-study with transplant-free survival, in which transplant-free survival was calculated from the follow-up echo-study. P<0.05 were considered statistically significant.
Results
Patient Characteristics and Echo Variables
Forty-three children with PAH were included: 26 patients (60%) were girls and 24 patients (56%) were newly diagnosed ones. The median age at the baseline echo-study was 8.0 years (IQR, 4.4-13.7; range, 0.4-21.5), with a median follow-up of 5.8 years (IQR, 3.1-8.8; range, 0.02-10.8). Twenty-five patients had idiopathic PAH and 18 had PAH-CHD. Table I in the Data Supplement provides an overview of all echo variables according to the echo-protocol, including the number of patients in which these measures turned out to be feasible (variables eligible to include in analyses are highlighted). Baseline characteristics, measures of disease severity, hemodynamics, Values are presented as median (interquartile range), mean±SD, or as numbers (percentage). 4ch indicates four chamber view; BSA, body surface area; CI, cardiac index; IPAH, idiopathic pulmonary arterial hypertension; lax, long axis; LV, left ventricle; mPAP, mean pulmonary arterial pressure; mRAP, mean right atrial pressure; N.A., not applicable; NT-pro-BNP, N-terminal-pro-B-type natriuretic peptide; PAH-CHD, pulmonary arterial hypertension associated with congenital heart disease; perp sax, perpendicular to septum short axis view; PVRi, indexed pulmonary vascular resistance; RA, right atrium; RV, right ventricle; RV/LV, right-to-left ventricular dimension ratio; sax, short axis; TAPSE, tricuspid annular plane systolic excursion; and WHO-FC, World Health Organization Functional Class.
*P value from analysis on original data set, before imputation of missing values. †P value from pooled analysis on 15 imputed data sets generated using multiple imputation with 20 iterations. ‡Fisher Exact test used to calculate P value. Echocardiography in Pediatric PAH and echo variables eligible for analysis are shown in Table 1 , stratified by type of PAH. The congenital heart defects of the patients with PAH-CHD are detailed in Table 2 .
Disease Severity
At time of the first echo-study, 74% of the patients were in WHO-FC III or IV. Treatment was according to the evolving treatment algorithm for PAH during the study period. Thirty patients (70%) were treatment naive at the start of the study. Thirteen were already on targeted PAH-treatment: calcium channel blockers (n=5), bosentan (n=5), beraprost (n=1), epoprostenol (n=1), and calcium channel blockers in combination with epoprostenol (n=1). Clinical, hemodynamic, and echocardiographic baselinecharacteristics, stratified by WHO-FC are shown in Table 3 . RA and RV dimensions, right-to-left ventricular dimension ratio (RV/LV ratio), RV ejection time, and TAPSE differed significantly among patients in different WHO-FC. Table 4 shows correlations between echo variables and WHO-FC and NT-pro-BNP. RA and RV dimensions, RV/LV ratio, eccentricity index, and TAPSE were significantly associated with WHO-FC. Although RV/LV ratio, left ventricular (LV) dimensions, RV acceleration time, and TAPSE tended to correlate with NT-pro-BNP (P<0.100), these correlations did not reach statistical significance.
In a subgroup of 21 patients, RHC had been performed within 2 months from the baseline echo-study. Table 5 shows correlations between echo variables and hemodynamics. RA and RVdimensions correlated with mean right atrial pressure, indexed pulmonary vascular resistance, and cardiac index; RV/LV ratio (short axis), eccentricity index, and RV ejection time correlated with indexed pulmonary vascular resistance and mean pulmonary-to-systemic arterial pressure ratio; LV dimension (short axis) correlated with cardiac index and mean pulmonary-to-systemic arterial pressure ratio, and TAPSE correlated with mean right atrial pressure.
Outcome
Over a median follow-up period of 5.8 (IQR, 3.1-8.8; range, 0.02-10.8,) years, 15 patients died and 3 underwent lungtransplantation. Overall cumulative survival stratified by WHO-FC is shown in Figure 1 . Univariable Cox regression analysis showed that higher WHO-FC was associated with a higher risk of death or lung-transplantation ( Figure 2 ). Smaller LV dimensions, higher RV/LV ratio, lower TAPSE, and lower RV ejection time were also associated with death or lungtransplantation ( Figure 3 ). Follow-up echocardiography was performed at a median follow-up time of 3.6 months (IQR, 2.7-5.4; range, 0.2-13.1) and revealed similar echo variables to be associated with outcome ( Figure 3) .
Discussion
This early descriptive study demonstrates that conventional transthoracic echo variables, including RA-, RV-, and LV dimensions and RV-functional variables correlate with disease severity and outcome in pediatric PAH. Previous studies on the use of echocardiography in pediatric PAH mostly focused on detection of elevated pulmonary artery pressure in patients suspected for pulmonary hypertension and its use as screening tool in populations at risk. However, only few focused on the potential role of echocardiography in guiding patient management in pediatric PAH. [34] [35] [36] 39 For decision-making in the management of patients with PAH, several diagnostic tools are used. In adults, goal-oriented treatment strategies are recommended, using 6MWD, WHO-FC, RHC, and NT-pro-BNP to guide treatment. Also, RV function has been demonstrated to be an important determinant of prognosis in PAH, where cMRI is currently considered to be the gold standard to evaluate RV function. 16 Its potential to assess disease severity, predict prognosis, and guide management in PAH has recently been advocated. [11] [12] [13] 45 In children with PAH, however, the use of such recommended tools is hampered, due to reasons of insufficient validation in pediatric PAH or lack of feasibility in young children. For instance, the prognostic value of 6MWD in young children is not clear, whereas only a minority of children is able to perform a reliable 6-minute-walk-test. This was illustrated in the TOPP registry, where 6MWD was available in only 38% of children in a global cohort. 3 Also, the use of WHO-FC has been claimed to be limited in young children because of its subjective nature and limited applicability, although several pediatric studies have now shown WHO-FC to be a useful predictor of outcome also in pediatric PAH. 6, 46 An adapted functional classification for children has been proposed, but has not been validated yet. 47 RHC has been shown to yield prognostically important measures, but its feasibility is hampered by the frequent need for sedation or general anesthesia and the relatively high major complication rate in children. 3 Recently, cMRI-derived RV ejection fraction and LV stroke volume index were demonstrated to be strong predictors of survival in 100 children with idiopathic pulmonary arterial hypertension or PAH-CHD. 12 However, the value of cMRI as diagnostic tool may be restricted by reduced feasibility in young children without sedation or general anesthesia and limited accessibility to required infrastructure and expertise on a global scale.
In view of the drawbacks of these currently available follow-up modalities, feasible, validated and easily accessible tools to assess disease severity and prognosis in pediatric PAH are urgently needed and conventional echocardiography may thus be such a tool. Previous studies in adults and children with PAH, often studying a single echo variable, have suggested echo variables to be associated with outcome in PAH. This study, however, provides a comprehensive overview of multiple conventional echo variables within the perspective of the patient's clinical setting and shows that several echo Values are presented as median (interquartile range), mean±standard deviation, or as numbers (percentage). 4ch indicates four chamber view; BSA, body surface area; CI, cardiac index; lax, long axis; LV, left ventricle; mPAP, mean pulmonary arterial pressure; mRAP, mean right atrial pressure; N.A., not applicable; NT-pro-BNP, N-terminal-pro-B-type natriuretic peptide; perp sax, perpendicular to septum short axis view; PVRi, pulmonary vascular resistance; RA, right atrium; RV, right ventricle; RV/LV, right-to-left ventricular dimension ratio; sax, short axis; TAPSE, tricuspid annular plane systolic excursion; and WHO-FC, World Health Organization functional class.
*P value from analysis on original data set, before imputation of missing values †P value from pooled analysis on 15 imputed data sets, generated using multiple imputation with 20 iterations. ‡Fisher Exact test used to calculate P value.
variables correlate with disease severity and outcome. In clinical practice, echocardiography may, therefore, function as an adjuvant to WHO-FC and NT-pro-BNP in the subjective and often difficult clinical assessment of disease severity in children with PAH. Survival in PAH is hypothesized to be closely related with RV function. 2 In congruence with adults with PAH, this study showed echocardiographic measures of RV function, including TAPSE and RV ejection time, to be associated with outcome in pediatric PAH. An important finding in this study is that echo variables that were identified at baseline were also predictive when collected at follow-up visits. Although the effect of treatment-initiation on specific variables was not evaluated, the persistence of their predictive value during follow-up underscores the potential value of echocardiography in defining treatment strategies in children with PAH.
In addition to RV-functional echo variables, LV dimensions also showed correlations with survival. This is in line with previous cMRI studies in children and adults, demonstrating the prognostic significance of LV dimensions and LV function in PAH. 12, 45 It is debated whether the reduced LV dimensions in advanced PAH-disease are merely a result of an imbalanced RV/LV ratio because of compression by a dilated high-pressure RV and prolonged systolic RV contraction or whether these reduced LV dimensions could also be due to ventricular interdependence-related failure of the LV structure and function. Because previous studies investigating echocardiography in PAH predominantly focused on right heart variables, more studies are needed to gain more insight in this. Recently, a study on echocardiography in adults with PAH identified reduced systolic strain of the LV-free wall as a predictor of early mortality. 48 The observed correlation of echocardiography with both disease severity and outcome is supported by our finding, in a subgroup, that the echo variables were also associated with hemodynamic measures. The relationship of echocardiographic characterization of the RV with hemodynamics was recently further supported by Di Maria et al, 10 who showed TAPSE and RV-fractional-area-change to be associated with RV-stroke-work, which is a hemodynamic measure integrating information on RV performance and ventricular-vascular coupling.
Our main observations are highly in line with adult findings. RA dimensions, 22 ventricular dimensions, 27 RV/LV ratio, 49 and TAPSE, 18, 50 have already been shown to carry prognostic value in adults. RV-myocardial performance (Tei) index, 28 eccentricity index, 18 and the presence of pericardial effusion, 23, 24 carry prognostic value in adults but were not able to be identified as potential predictors of outcome in this pediatric study. Also, a reduced tricuspid annular peak systolic velocity (S′), or reduced tissue Doppler imaging velocities (systolic myocardial velocity and early diastolic myocardial relaxation velocity), as reported in previous pediatric studies, could not be identified as predictors of outcome. 38 This might be because of lack of power in this study, as pericardial effusion was rare in the studied children, whereas tissue Doppler variables and Tei-index, although prescribed by the echo-protocol, could often not be appropriately assessed in our population. This not only prohibits robust conclusions on the prognostic value of these variables in pediatric PAH but may also question the feasibility of collecting accurate measurements for these variables in all children. To illustrate, the prognostic value of increased ratio of RV-systolic/diastolic phase, as reported by Alkon et al, 34 could not be confirmed in our study. These investigators assessed the RV systolic to diastolic duration ratio, from the Doppler flow signal of tricuspid valve regurgitation. In our study, 31 patients (76%) had tricuspid regurgitation ≤grade I, making this echo variable less feasible for analysis in our population.
Newer techniques may further enhance the value of echocardiography as a bedside tool in children with PAH. Recently, speckle tracking echocardiography, an angle-independent Values are presented as Pearson correlation coefficient with accompanying P-value, unless otherwise indicated. 4ch indicates four chamber view; CI, cardiac index; lax, long axis; LV, left ventricle; mPAP/mSAP, mean pulmonary-to-systemic arterial pressure ratio; mRAP, mean right atrial pressure; perp sax, perpendicular to septum short axis view; PVRi, indexed pulmonary vascular resistance; PVR/SVR, pulmonary-tosystemic vascular resistance ratio; RA, right atrium; RV, right ventricle; RV/LV, right-to-left ventricular dimension ratio; sax, short axis; and TAPSE, tricuspid annular plane systolic excursion.
*Results are from pooled analysis on 15 imputed data sets, generated using multiple imputation with 20 iterations in which missing echo values were imputed.
†Spearman correlation used instead of Pearson correlation, because of non-normality. As hemodynamic data were not imputed, the presented results are from a subgroup of 21 patients. technique to quantify myocardial motion, demonstrated decreased RV and LV longitudinal systolic strain in adults with PAH and serial measures have been suggested to predict therapy effect and outcome in these patients.
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Strengths and Limitations
This study was part of the Dutch nationwide registry for PH in childhood, which encompasses all diagnosed children with PAH in The Netherlands. The use of a consistent observational registry approach with a high level of methodological standardization in a well-described representative study population allows for observational studies as the current. However, this approach does not replace a prospective (multicenter) study design and is inevitably associated with important limitations.
We studied a high number of echo variables in a relatively small cohort, which may have led to overestimation of found correlations. Also, heterogeneity in patients' diagnosis, (idiopathic/heritable PAH versus PAH-CHD) may limit the interpretation of the findings. During follow-up, treatment strategies might have changed according to evolving treatment guidelines, which could not be accounted for in survival analyses. The diagnostic approach including the echo-protocol remained unchanged during the observation time. Data of tissue Doppler imaging variables were incomplete and, therefore, not included in the analyses. These limitations will limit confidence and preclude robust conclusions. Nevertheless, the results of this study are highly in line with reports on echocardiographic predictors in adult patients. 18, 22, 27, 49, 50 Therefore, and in view of the preliminary nature of the current data, this study should be considered an early exploratory pediatric study supporting the potential use of echocardiography in children with PAH.
Suggestions for Future Research
To increase confidence and to be able to perform multivariable analyses, a prospective, multicenter study should be designed, including a high number of children with PAH. Then, a multivariable approach could yield insight in which of the identified parameters are independent predictors of outcome. In addition, longitudinal studies are needed to determine the prognostic value of treatment-induced changes, to identify which echo variables could be used in defining treatment goals.
Conclusions
This early descriptive study shows that easily acquired and widely available conventional echocardiographic characteristics, from both the right and LV, correlate with disease severity and outcome in children with PAH. These characteristics include RA-, RV-, and LV dimensions, RV/LV ratio's and RVfunctional variables. Recognizing the current, unmet need for goal-oriented treatment strategies in pediatric PAH, echocardiography might play an adjuvant role in the assessment of disease severity and in guiding treatment in young children,
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